GAST and Zollinger-Ellison syndrome: A retrospective study evaluated the efficacy of octreotide LAR (30 mg/month) for 12–75 months as a first-line treatment in 20 patients with one or more early-stage duodeno-pancreatic NETs (70% non-functioning, 25% Zollinger-Ellison syndrome, and 5% insulinomas) <20 mm related to MEN-1 and demonstrated an objective tumor response in two (10%) patients (both affected with a non-functioning NETs) and stable disease in 16 (80%) patients (12 with non-functioning NETs and four with a gastrin-secreting NETs).